The Experts below are selected from a list of 2574 Experts worldwide ranked by ideXlab platform
Ashok Handa - One of the best experts on this subject based on the ideXlab platform.
-
Quick Reference Guide to apixaban.
Vascular health and risk management, 2017Co-Authors: Katherine Hurst, John M. O’callaghan, Ashok HandaAbstract:Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and consequent prescription of specified doses) and no requirement for routine monitoring. Apixaban is a selective factor Xa inhibitor, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation and in the prevention and treatment of acute VTE. Like many of the DOACs, it has a fast onset of action and works to deliver predictable coagulation results. Multiple randomized controlled trials including ARISTOTLE and AMPLIFY have shown apixaban to be noninferior to vitamin K antagonists in the prevention of stroke and VTE, with a good safety profile. This article aims to review the use of apixaban for the prevention and treatment of thromboembolic disease, highlighting the key study results that have led to its current licensing and use.
-
Quick Reference Guide to the new oral anticoagulants
Journal of Vascular Surgery, 2016Co-Authors: Katherine Hurst, Regent Lee, Ashok HandaAbstract:After the commissioning of new oral anticoagulants for the treatment and prevention of thrombosis, these medications are now widely used within clinical settings. Increasing numbers of patients present to the health services on anticoagulant medications, and it is therefore imperative for surgeons to be aware of the new therapeutic treatments available and how patients will benefit from such interventions. This review highlights the most pertinent learning points for surgeons regarding the indications, pharmacokinetics, and perioperative management of these new oral medications, as a Quick Reference Guide.
Cynthia J Carney - One of the best experts on this subject based on the ideXlab platform.
-
Quick Reference Guide for clinicians number 12 managing otitis media with effusion in young children
Archives of Otolaryngology-head & Neck Surgery, 1994Co-Authors: Sylvan E Stool, Alfred O Berg, Stephen Berman, Cynthia J CarneyAbstract:This Quick Reference Guide for Clinicians contains highlights from the Clinical Practice Guideline, Otitis Media with Effusion in Young Children . The Otitis Media Guideline Panel, a private-sector panel of health care providers, developed the Guideline after comprehensively analyzing the research literature and current scientific knowledge of the development, diagnosis, and treatment of otitis media with effusion in young children. Specific recommendations are given for the management of otitis media with effusion in young children age 1 through 3 years with no craniofacial or neurologic abnormalities or sensory deficits. The natural history of otitis media with effusion, the functional impairments that may result from otitis media with effusion, and the difficulty of measuring the effects of medical and surgical interventions on long-term outcomes are included. The medical interventions studied involve antibiotic therapy, steroid therapy, and antihistamine/decongestant therapy. The surgical interventions studied involve myringotomy with insertion of tympanostomy tubes, adenoidectomy, and tonsillectomy. Short-term outcomes addressed are resolution of effusion and restoration of hearing.
Amy Jayne Mcknight - One of the best experts on this subject based on the ideXlab platform.
-
a Quick Reference Guide for rare disease supporting rare disease management in general practice
British Journal of General Practice, 2020Co-Authors: Ashleen Crowe, Helen Mcaneney, Patrick J Morrison, Margaret Cupples, Amy Jayne McknightAbstract:A rare disease is defined as any life-limiting or chronically debilitating disease affecting <1 person in 2000, with many rare diseases affecting <1 person per 100 000. There are approximately 8000 rare diseases, with recent analysis suggesting a conservative prevalence of 3.5–5.9%.1 Over the last decade, tremendous advances have been made in rare disease identification, treatment, and support. This has been largely driven by an increasingly vehement consolidated patient voice and an EU directive (2009) that all member states required a rare disease plan/strategy by 2013. In 2013, the UK strategy for rare disease was published,2 followed by the launch of rare disease implementation plans for the devolved nations (Scotland in 2014;3 Northern Ireland in 2015;4 Wales in 20175). Rare diseases have major unmet medical needs. Healthcare professionals and rare disease charities often hear tragic stories of patients with rare life-threatening diseases where responsible doctors have been unable to help as they have never heard of the condition, nor seen a similar case presentation, nor found relevant knowledge and expertise online. More than 80% of individuals report difficulty in accessing relevant information and >70% of GPs struggle to identify or manage rare diseases. A long diagnostic odyssey is common, with patients often feeling misunderstood, isolated, vulnerable, receiving …
Katherine Hurst - One of the best experts on this subject based on the ideXlab platform.
-
Quick Reference Guide to apixaban.
Vascular health and risk management, 2017Co-Authors: Katherine Hurst, John M. O’callaghan, Ashok HandaAbstract:Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and consequent prescription of specified doses) and no requirement for routine monitoring. Apixaban is a selective factor Xa inhibitor, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation and in the prevention and treatment of acute VTE. Like many of the DOACs, it has a fast onset of action and works to deliver predictable coagulation results. Multiple randomized controlled trials including ARISTOTLE and AMPLIFY have shown apixaban to be noninferior to vitamin K antagonists in the prevention of stroke and VTE, with a good safety profile. This article aims to review the use of apixaban for the prevention and treatment of thromboembolic disease, highlighting the key study results that have led to its current licensing and use.
-
Quick Reference Guide to the new oral anticoagulants
Journal of Vascular Surgery, 2016Co-Authors: Katherine Hurst, Regent Lee, Ashok HandaAbstract:After the commissioning of new oral anticoagulants for the treatment and prevention of thrombosis, these medications are now widely used within clinical settings. Increasing numbers of patients present to the health services on anticoagulant medications, and it is therefore imperative for surgeons to be aware of the new therapeutic treatments available and how patients will benefit from such interventions. This review highlights the most pertinent learning points for surgeons regarding the indications, pharmacokinetics, and perioperative management of these new oral medications, as a Quick Reference Guide.
Gerald B. Healy - One of the best experts on this subject based on the ideXlab platform.
-
Quick Reference Guide for Clinicians: Managing Otitis Media With Effusion in Young Children: A Commentary
Archives of otolaryngology--head & neck surgery, 1994Co-Authors: Gerald B. HealyAbstract:In promoting the publication of Guidelines for the treatment of otitis media, the Agency for Health Care Policy and Research (Rockville, Md) has attempted to provide an orderly approach for clinicians to treat this most common of childhood illnesses. For this, the Agency is to be congratulated. A highly responsible panel representing a broad cross-sectional view point was used in this most difficult task.
